Related Experiment Video
Updated: Jun 20, 2025
Software-Assisted Quantitative Measurement of Osteoarthritic Subchondral Bone Thickness
Published on: March 18, 2022
TBK1 pharmacological inhibition mitigates osteoarthritis through attenuating inflammation and cellular senescence in
Rui Lu1, Yunkun Qu2, Zhenggang Wang2
1Department of Thoracic Surgery, Zhongnan Hospital of Wuhan University, Wuhan, 430030, China.
Objectives:
TANK-binding kinase 1 (TBK1) is pivotal in autoimmune and inflammatory diseases, yet its role in osteoarthritis (OA) remains elusive. This study sought to elucidate the effect of the TBK1 inhibitor BX795 on OA and to delineate the underlying mechanism by which it mitigates OA.
Methods:
Interleukin-1 Beta (IL-1β) was utilized to simulate inflammatory responses and extracellular matrix degradation in vitro. In vivo, OA was induced in 8-week-old mice through destabilization of the medial meniscus surgery. The impact of BX795 on OA was evaluated using histological analysis, X-ray, micro-CT, and the von Frey test. Additionally, Western blot, RT-qPCR, and immunofluorescence assays were conducted to investigate the underlying mechanisms of BX795.
Results:
Phosphorylated TBK1 (P-TBK1) levels were found to be elevated in OA knee cartilage of both human and mice. Furthermore, intra-articular injection of BX795 ameliorated cartilage degeneration and alleviated OA-associated pain. BX795 also counteracted the suppression of anabolic processes and the augmentation of catabolic activity, inflammation, and senescence observed in the OA mice. In vitro studies revealed that BX795 reduced P-TBK1 levels and reversed the effects of anabolism inhibition, catabolism promotion, and senescence induction triggered by IL-1β. Mechanistically, BX795 inhibited the IL-1β-induced activation of the cGAS-STING and TLR3-TRIF signaling pathways in chondrocytes.
Conclusions:
Pharmacological inhibition of TBK1 with BX795 protects articular cartilage by inhibiting the activation of the cGAS-STING and TLR3-TRIF signaling pathways. This action attenuates inflammatory responses and cellular senescence, positioning BX795 as a promising therapeutic candidate for OA treatment.
The Translational Potential Of This Article:
This study furnishes experimental evidence and offers a potential mechanistic explanation supporting the efficacy of BX795 as a promising candidate for OA treatment.
Insights
The TBK1 inhibitor BX795 reduces inflammation and cartilage damage in osteoarthritis (OA). This study shows BX795 is a promising therapeutic for OA by targeting key inflammatory pathways.
Area of Science:
- Biochemistry
- Immunology
- Orthopedics
Background:
- TANK-binding kinase 1 (TBK1) plays a role in inflammatory diseases.
- The role of TBK1 in osteoarthritis (OA) is not well understood.
- Investigating TBK1's role in OA could reveal new therapeutic targets.
Purpose of the Study:
- To investigate the effect of the TBK1 inhibitor BX795 on osteoarthritis.
- To elucidate the mechanism by which BX795 mitigates OA.
- To assess BX795 as a potential therapeutic for OA.
Main Methods:
- OA was induced in mice and treated with BX795.
- Histological analysis, X-ray, micro-CT, and pain tests were used for evaluation.
- Western blot, RT-qPCR, and immunofluorescence assays identified molecular mechanisms.
Main Results:
- Elevated phosphorylated TBK1 (P-TBK1) was observed in OA cartilage.
- BX795 treatment reduced cartilage degeneration and OA pain in mice.
- BX795 inhibited IL-1β-induced activation of cGAS-STING and TLR3-TRIF pathways in chondrocytes.
Conclusions:
- TBK1 inhibition with BX795 protects articular cartilage in OA.
- BX795 attenuates inflammation and cellular senescence.
- BX795 demonstrates potential as a therapeutic agent for osteoarthritis.
Related Concept Videos
01:20The JAK-STAT Signaling Pathway
01:16TGF - β Signaling Pathway
02:26NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The...